Core Insights - Healthcare apparel company Figs reported Q3 CY2025 revenue of $151.7 million, an 8.2% year-on-year increase, exceeding analyst estimates of $142.5 million [1][5] - The company achieved a non-GAAP profit of $0.05 per share, significantly above the consensus estimate of $0.02 [1][5] - Adjusted EBITDA reached $18.85 million, with a margin of 12.4%, surpassing analyst expectations of $12.38 million [5] Management Commentary - Management attributed the strong performance to consistent execution across core products and disciplined promotional strategies, leading to higher average order values and customer engagement [3][4] - CEO Trina Spear highlighted broad-based growth in scrubwear and the U.S. market, along with improvements in product fit and returns processing [3] - The company plans to maintain momentum through increased inventory investments, new product introductions, and targeted international growth, including the launch of FIBERx fabric at the 2026 Winter Olympics [3] Financial Performance - Operating margin improved to 6.4%, up from -6.2% in the same quarter last year [5] - Active customers increased to 2.78 million, representing a year-on-year growth of 108,000 [5] - Market capitalization stands at $1.23 billion [5] Strategic Initiatives - The deliberate reduction in promotional activity led to higher average order values and improved profitability, with more sales occurring at full price [6] - Growth was primarily driven by the core scrubwear category, with new silhouettes and improved fits reducing return rates [6] - Figs expanded its international presence from 33 to nearly 60 markets, with recent launches in Japan and South Korea, and an upcoming debut in China [6] Product Development - Non-scrubwear categories, including underscrubs, compression socks, and footwear, saw renewed momentum due to targeted product launches [6] - Operational efficiency gains were achieved through supply chain optimization and reduced marketing expenses, despite facing higher tariffs on imports [6]